What is it about?
This paper serves as an update of the overall stem cell industry market. We quantify the amount of investment that has gone into the stem cell market, the types of investment (e.g. VC, IPOs, bonds), and overall growth of the market from 2012 to 2016.
Featured Image
Why is it important?
Stem cells have been heralded as cutting-edge and with significant clinical potential. However, the market is still young. This paper provides numbers quantifying the growth of the overall stem cell industry, as well as the significant investment ($23B) that has gone into research and development. This paper provides an overall layout for the field as a whole, and is relevant for researchers, clinicians, and investors.
Perspectives
At surface value, this paper is structured like a traditional equity research report and may be dry to read. However, I believe the information provided is incredibly relevant. In particular, finding the $ investment into stem cell companies, and the overall growth of the market are highly significant metrics that help shed light into the stem cell industry.
Mitchell Ng
Cleveland Clinic
Read the Original
This page is a summary of: Stem cell industry update: 2012 to 2016 reveals accelerated investment, but market capitalization and earnings lag, Cytotherapy, October 2017, Elsevier,
DOI: 10.1016/j.jcyt.2017.07.006.
You can read the full text:
Contributors
The following have contributed to this page
